Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Onconetix (ONCO) Notes Payables (2023 - 2025)

Onconetix (ONCO) has disclosed Notes Payables for 2 consecutive years, with $9.8 million as the latest value for Q3 2024.

  • On a quarterly basis, Notes Payables fell 23.84% to $9.8 million in Q3 2024 year-over-year; TTM through Sep 2024 was $9.8 million, a 23.84% decrease, with the full-year FY2023 number at $9.6 million, changed N/A from a year prior.
  • Notes Payables was $9.8 million for Q3 2024 at Onconetix, down from $10.1 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $12.9 million in Q3 2023 to a low of $9.6 million in Q4 2023.